HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.

Abstract
Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular- targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimetry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing (90)Y, (188)Re, (166)Ho, (149)Pm, (64)Cu, and (177)Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for (90)Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for (90)Y to 1% for (177)Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.
AuthorsWilliam H Miller, Christine Hartmann-Siantar, Darrell Fisher, Marie-Anne Descalle, Tom Daly, Joerg Lehmann, Michael R Lewis, Timothy Hoffman, Jeff Smith, Peter D Situ, Wynn A Volkert
JournalCancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 20 Issue 4 Pg. 436-49 (Aug 2005) ISSN: 1084-9785 [Print] United States
PMID16114992 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Copper Radioisotopes
  • Radioisotopes
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • Lutetium
  • Rhenium
  • Holmium
  • Promethium
Topics
  • Animals
  • Copper Radioisotopes (therapeutic use)
  • Disease Models, Animal
  • Holmium (therapeutic use)
  • Lutetium (therapeutic use)
  • Mice
  • Mice, Nude
  • Models, Statistical
  • Models, Theoretical
  • Promethium (therapeutic use)
  • Radioimmunotherapy
  • Radioisotopes (therapeutic use)
  • Radiometry
  • Radiopharmaceuticals (pharmacokinetics)
  • Rhenium (therapeutic use)
  • Tissue Distribution
  • Yttrium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: